ClinicalTrials.gg
WithdrawnNCT00601978Updated Apr 30, 2012

Carbidopa/Levodopa Versus Carbidopa/Levodopa/Entacapone on Markers of Event Related Potentials (ERPs) in Patients With Idiopathic Parkinson's Disease (PD) and End-of-dose Wearing Off

A Phase 4 interventional study of carbidopa/levodopa and Carbidopa/Levodopa/Entacapone in Parkinson's Disease, sponsored by Novartis Pharmaceuticals. Withdrawn. Open to participants aged 45 Years to 75 Years. Per ClinicalTrials.gov, last updated 2012-04-30.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Why this study was withdrawn
Business decision brand strategy; no patients enrolled

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
45 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies testing carbidopa in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. Carbidopa · Parkinson Disease.

Enrollment
24th of 24
0 · median 46
Started
2008
with 4 others
Phase 4
9 of 24
1 open now
Registered
11th of 24
by date
Lead sponsor
3 of 24
Novartis Pharmaceuticals

Among the 24 studies testing carbidopa in Parkinson Disease, this one is the 24th largest by enrollment, is one of 5 that started in 2008, is one of 9 in phase 4, and was the 11th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,087 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 24 studies testing carbidopa in Parkinson Disease is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About carbidopa

Carbidopa: first FDA approval 1975 (SINEMET), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 750 Parkinson Disease studies recruiting now, 312 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 190 take healthy volunteers.

This study: 45 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies testing carbidopa in Parkinson Disease, or all of them as a file.
02

Study summary

This study will evaluate the effects of immediate release (IR) carbidopa levodopa versus the effects of immediate-release carbidopa/levodopa on ERP parameters in patients with idiopathic PD.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Parkinson's disease
  • carbidopa/levodopa/entacapone
  • carbidopa/levodopa
  • non-motor symptoms
  • event-related potential
  • ERP
  • EEG
  • electroencephalogram
04

Who can participate

Ages eligible
45 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged 45 to 75 years (inclusive)
  2. Patients with an score of at least 25 at the screening visit.
  3. Patients who experience EODWO, which is the re-emergence of PD symptoms during the waking hours, as determined by a WOQ-9 score of at least one motor symptom of wearing off
  4. Patients taking a stable dose of immediate-release carbidopa/levodopa for at least 4 weeks prior to randomization, at an equivalent total daily dose of levodopa between 300 to 600 mg/day.
  5. Patients who, in the investigator's judgement, are capable of satisfying the requirements of the protocol
  6. Patients who are willing and able to give written according to legal requirements.

Exclusion criteria

Exclusion Criteria:

  1. Diagnosis of secondary parkinsonism, atypical Parkinson's disease, or history, signs, or symptoms suggesting these diagnoses.
  2. Unstable Parkinson's disease as determined by the investigator.
  3. Disabling dyskinesia (a score of >2 on the Unified Parkinson's Disease Rating Scale [UPDRS] question #32, or a score of >2 on UPDRS question #33).
  4. Treatment with carbidopa/levodopa controlled-release or extended-release formulations (bedtime administration is acceptable). The use of controlled-release carbidopa/levodopa is not allowed on the evening before the visits in which efficacy assessments occur.
  5. Concomitant or previous treatment with certain medications or supplements as specified in the protocol.
  6. Patients who are unable to comply with the dosing requirements of the protocol, such that the first dose of study medication will be taken after the time of the first EEG and the second dose will be taken after completion of the third EEG.
  7. Diagnostic and Statistical Manual, Fourth Edition, Text Revision (; diagnosis of 1. dementia (of any cause); 2. moderate or severe major depression, present independent from the time of first diagnosis of PD, as defined by a QIDS-SR16 score of > 15; or 3. generalized anxiety disorder or panic disorder if made prior to the diagnosis of PD.
  8. DSM-IV-TR diagnosis of alcohol or substance abuse (excluding nicotine or caffeine) during the 3 months prior to randomization) or alcohol or substance dependence (excluding nicotine or caffeine) during the 6 months prior to randomization. Alcohol should be avoided within the 12 hours preceding the Week 6 and Week 12 visits.
  9. Nicotine use of >5 cigarettes (or equivalent in other forms of administration) per day. Nicotine use will not be permitted on the day of the Week 6 and Week 12 visits.
  10. Ingestion of >4 caffeinated beverages (or equivalent in other forms of administration) per day.
  11. History of major head injury, including skull fracture or a penetrating head injury, or a history of brain surgery.
  12. Past or current treatment by deep brain stimulation.
  13. History of of any organ system, treated or untreated, within the past 5 years whether or not there is evidence of local recurrence or , with the exception of localized basal cell carcinoma of the skin.
  14. Hearing loss or impairment that may prevent reliability of test results using auditory evoked potentials.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    1

    Immediate-Release Carbidopa/Levodopa

    Drug: carbidopa/levodopa

  • Active comparator
    2

    Carbidopa/Levodopa/Entacapone

    Drug: Carbidopa/Levodopa/Entacapone

Interventions

06

What researchers measure

Primary outcomes

  1. To evaluate the mean latency of the P300 component of the event-related potentials (ERPs) at four hours post study-drug administration

Secondary outcomes

  1. Mean latency of the P300 component of ERPs at pre-dose and 1 hours post-dose study drug administration

  2. Mean latency of the N100 component of ERPs at pre-dose, 1 hour post-dose and 4 hours post-dose study drug administration

  3. Pharmacokinetics at 9.25 and 12.55 hours post dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Nov 2009 and a completion of Nov 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 11, 2008
First posted
Jan 28, 2008
Start
Aug 2008
Primary completionActual
Nov 2009
CompletionActual
Nov 2009
Last update
Apr 30, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00601978
Responsible party
Sponsor
First posted
Jan 28, 2008
Start date
Aug 2008
Primary completion
Nov 2009
Completion
Nov 2009
Last update
Apr 30, 2012

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Carbidopa · Levodopa · Entacapone

Start the discussion